Tilak Receives Positive Opinion in Europe for Early Reimbursement of Odysight Telemonitoring Device
Paris-based Tilak Healthcare has received a positive opinion from the French National Health Authority (Haute Autorité de Santé, HAS) for the reimbursement of Odysight under the PECAN (Prise En Charge Anticipée des dispositifs médicaux Numériques – Early Access to Digital Medical Devices) scheme. This decision paves the way for broader patient access to the ophthalmology telemonitoring in France and Europe.
“The reimbursement of Odysight is a recognition of our vision and the culmination of years of collective work,” said Edouard Gasser, co-founder and CEO of Tilak Healthcare. “We thank public authorities, our partners, physicians, and patients for their trust. We are thrilled to share our innovation more widely and make it accessible to as many patients as possible. This recognition reinforces our position as the French and European leader in ophthalmology telemonitoring. We will now focus on expanding our scientific evidence base to demonstrate the clinical impact of our innovations, with the goal of becoming the global leader in at-home monitoring of visual disorders and strengthening new strategic alliances that create real value.”
Odysight is a CE-marked, prescription-only medical device available on smartphones and tablets. It enables patients with chronic maculopathies—such as age-related macular degeneration (AMD)—to perform self-administered vision tests to monitor visual acuity between clinical visits. Results are automatically transmitted to the treating physician, who receives an alert in case of vision decline, allowing for timely intervention and personalized follow-up.
“For a long time, the ‘Amsler grid on the fridge’ was the only option for home vision monitoring,” said Suehanna Nagi, President of the AMD Association. “Odysight is a clinically validated, easy-to-use, and fun application that has drastically improved patient follow-up at home. The patient–physician connection is greatly strengthened, allowing for early consultations in case of confirmed visual acuity decline.”